{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:33:49Z","timestamp":1791304429359,"version":"4.3.1"},"reference-count":53,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Int AIDS Soc."],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The potential of pre\u2010exposure prophylaxis (PrEP), as a highly effective and empowering HIV prevention intervention, has not yet been realized. Despite the recent acceleration in the scale\u2010up of oral PrEP, there is a substantial unmet PrEP need, and the world is not on track to meet the 2025 prevention targets. New PrEP products, and service delivery approaches, could support greater access, uptake, persistence and effective use. This commentary discusses how offering choice in PrEP products and service delivery innovations could transform global HIV prevention efforts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Although oral PrEP accounts for almost all PrEP use to date, slow rollout and challenges in effective use and persistence have limited the global impact. Innovative products like long\u2010acting injectable cabotegravir and injectable lenacapavir can overcome some of the challenges associated with oral PrEP. Expanding PrEP choices is also essential for addressing diverse individual preferences and maximizing prevention outcomes. Real\u2010world evidence suggests that offering increased options can drive demand and increase coverage of prevention.<\/jats:p>\n                    <jats:p>Equally critical is tailoring service delivery through differentiated service delivery (DSD) models that prioritize accessibility and user needs and preferences, including integration of PrEP within other valued services. DSD models, including peer\u2010led, pharmacy\u2010based and telehealth approaches, have demonstrated success and acceptability for oral PrEP, but innovation is needed to adapt to long\u2010acting injectable options. For example, regulatory and policy support are essential to support task\u2010sharing with community health worker involvement may enable broader reach.<\/jats:p>\n                    <jats:p>Programmatic challenges, including PrEP product and service delivery costs, updating monitoring and evaluation and ensuring stakeholder support, must also be addressed. Scaling up new PrEP products using a precision prevention lens could help to optimize approaches for achieving impact.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The new era of PrEP choice, with new long\u2010acting PrEP products and DSD options, presents countries with an extraordinary opportunity to amplify prevention access, achieve higher prevention coverage and drive the meaningful reductions in new HIV acquisitions needed to end the HIV epidemic. Without coordinated and concerted efforts within countries and supported at the global level to leverage choice and embed it within the HIV prevention response, we risk prolonging the HIV epidemic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jia2.26498","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T07:27:33Z","timestamp":1751441253000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Seizing the moment: the potential of PrEP choice and innovation to transform HIV prevention"],"prefix":"10.1002","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2629-6407","authenticated-orcid":false,"given":"Heather\u2010Marie A.","family":"Schmidt","sequence":"first","affiliation":[{"name":"Global HIV, Hepatitis and STIs Programme World Health Organization  Geneva Switzerland"},{"name":"UNAIDS  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateo","family":"Prochazka","sequence":"additional","affiliation":[{"name":"Global HIV, Hepatitis and STIs Programme World Health Organization  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8714-8889","authenticated-orcid":false,"given":"Heather","family":"Ingold","sequence":"additional","affiliation":[{"name":"Global HIV, Hepatitis and STIs Programme World Health Organization  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushena","family":"Reza\u2010Paul","sequence":"additional","affiliation":[{"name":"Global HIV, Hepatitis and STIs Programme World Health Organization  Geneva Switzerland"},{"name":"UNAIDS Regional Office for Asia and the Pacific  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thato","family":"Chidarikire","sequence":"additional","affiliation":[{"name":"World Health Organization South Africa Office  Pretoria South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irvin","family":"Romyco","sequence":"additional","affiliation":[{"name":"World Health Organization Indonesia Office  Jakarta Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Rodolph","sequence":"additional","affiliation":[{"name":"Global HIV, Hepatitis and STIs Programme World Health Organization  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001145"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003494"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/13691058.2023.2270004"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/00224499.2021.1936440"},{"key":"e_1_2_9_6_1","unstructured":"The Global PrEP Tracker: PrEP Watch. AVAC;2022. Accessed May 16 2025.https:\/\/data.prepwatch.org."},{"key":"e_1_2_9_7_1","unstructured":"The urgency of now: AIDS at a crossroads.Geneva:Joint United Nations Programme on HIV\/AIDS;2024."},{"key":"e_1_2_9_8_1","volume-title":"WHO implementation tool for pre\u2010exposure prophylaxis (PrEP) of HIV infection: provider module for oral and long\u2010acting PrEP","year":"2024"},{"key":"e_1_2_9_9_1","unstructured":"The future of ARV\u2010based prevention and more. AVAC;2024. [updated 1 October 2024]. Accessed May 16 2025.https:\/\/avac.org\/resource\/infographic\/the\u2010future\u2010of\u2010arv\u2010based\u2010prevention\u2010and\u2010more\/."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/17437199.2021.1962386"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00050-4"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002797"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-023-04172-3"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30215-7"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(21)00074-6"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002790"},{"key":"e_1_2_9_17_1","volume-title":"HIV Epidemiology Annual Report 2022","year":"2023"},{"key":"e_1_2_9_18_1","volume-title":"HIV testing, PrEP, new HIV diagnoses and care outcomes for people accessing HIV services: 2024 report. The annual official statistics data release (data to end of December 2023)","author":"Kitt H","year":"2024"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00256-4"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00030-3"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00538-4"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00261-8"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407001"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411858"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26107"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2023.100432"},{"key":"e_1_2_9_27_1","volume-title":"PrEP product awareness, preferences, and past experiences among transgender women and men who have sex with men in Asia and Australia: The PrEP APPEAL Study Report","author":"Chan C","year":"2023"},{"key":"e_1_2_9_28_1","unstructured":"The HIV prevention choice manifesto for women and girls in Africa.African Women Prevention Community Accountability Board;2023."},{"key":"e_1_2_9_29_1","unstructured":"AzizR.AIDS 2024: studies show strong user preference for long\u2010acting injectable PrEP.Arlington:Infectious Diseases Society of America;2024[updated 23 July 2024]. Accessed May 16 2025.https:\/\/www.idsociety.org\/science\u2010speaks\u2010blog\/2024\/aids\u20102024\u2010studies\u2010show\u2010strong\u2010user\u2010preference\u2010for\u2010long\u2010acting\u2010injectable\u2010prep\/#\/+\/0\/publishedDate_na_dt\/desc\/."},{"key":"e_1_2_9_30_1","unstructured":"Ndhlovu AP KawangaL PhiriD NyumbuM.Long\u2010acting injectable cabotegravir (CAB\u2010LA) pilot implementation at primary healthcare level in resource\u2010limited settings: early real\u2010world evidence from the USAID DISCOVER\u2010Health Project in Zambia.HIV R4P 2024.Lima:International AIDS Society;2024. p.22\u20133."},{"issue":"12","key":"e_1_2_9_31_1","article-title":"Dynamic choice HIV prevention with cabotegravir long\u2010acting injectable in rural Uganda and Kenya: a randomised trial extension","volume":"11","author":"Kamya MR","year":"2024","journal-title":"Lancet HIV"},{"key":"e_1_2_9_32_1","unstructured":"SubedarH.Implementing PrEP choice: experiences from South Africa\u2014update on PrEP (including long\u2010acting products) South Africa.HIV Research for Prevention (HIVR4P).Lima Peru;2024."},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00365-4"},{"key":"e_1_2_9_34_1","volume-title":"Differentiated and simplified pre\u2010exposure prophylaxis for HIV prevention: update to WHO implementation guidance","year":"2022"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0266280"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26055"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-061503"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-076545"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-024-04519-4"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25965"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25963"},{"key":"e_1_2_9_42_1","volume-title":"Consolidated guidelines on differentiated HIV testing services","year":"2024"},{"key":"e_1_2_9_43_1","first-page":"11","article-title":"Task shifting and task sharing in the health sector in sub\u2010Saharan Africa: evidence, success indicators, challenges, and opportunities","volume":"46","author":"Adeagbo O","year":"2023","journal-title":"Pan Afr Med J"},{"key":"e_1_2_9_44_1","unstructured":"PatelRR GoldenM KelleyE McLaughlinR KeitaR FesslerD et\u00a0al.Feasibility of long acting injectable cabotegravir PrEP initiation and administration by community health workers and early aspects of the PrEP injection care continuum in a primary care center in Washington D.C.International AIDS Society Conference; 22\u201326 July 2023.Brisbane Australia;2023."},{"key":"e_1_2_9_45_1","unstructured":"Briefing Note: Cost and supply security benefits of using tenofovir disoproxil fumarate + lamivudine (TDF\/3TC) for oral pre\u2010exposure prophylaxis (PrEP).Geneva:The Global Fund USAID PEPFAR;2024."},{"key":"e_1_2_9_46_1","unstructured":"WeiL.CAB\u2010LA pricing (Personal Communication 11 November2024)."},{"key":"e_1_2_9_47_1","unstructured":"MalanM.\u201cSouth Africa \u2018can't afford\u2019 to pay for new anti\u2010HIV drug despite cut\u2010price offer\u201d. The Guardian. 2024. 17 Nov 2023."},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae305"},{"issue":"5","key":"e_1_2_9_49_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0268240","article-title":"Cost\u2010effectiveness and impact of pre\u2010exposure prophylaxis to prevent HIV among men who have sex with men in Asia: a modelling study","volume":"17","author":"Martin\u2010Hughes R","year":"2022","journal-title":"PLoS One"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00029-7"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lansea.2022.100097"},{"key":"e_1_2_9_52_1","volume-title":"HIV Prevention 2025 \u2010 Road Map: Getting on track to end AIDS as a public health threat by 2030","year":"2022"},{"key":"e_1_2_9_53_1","unstructured":"NaidooNP.Implementing PrEP choice: experiences from South Africa\u2014examples of studies\u2014CATALYST South Africa.HIV Research for Prevention (HIVR4P) 2024;Lima Peru;2024."},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-024-00704-1"}],"container-title":["Journal of the International AIDS Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.26498","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T10:57:04Z","timestamp":1752145024000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jia2.26498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":53,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1002\/jia2.26498"],"URL":"https:\/\/doi.org\/10.1002\/jia2.26498","archive":["Portico"],"relation":{},"ISSN":["1758-2652","1758-2652"],"issn-type":[{"value":"1758-2652","type":"print"},{"value":"1758-2652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2024-11-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e26498"}}